We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£495.00
It has never been this cheap. We have no record of a lower price.
£495 today · cheaper than every other day in the last 3 months
The 2023-2028 Outlook for Diabetic Retinopathy Treatments in Japan
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 86 days · 86 data points (no recent data)
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 86 days • 1 price levels
Price Analysis
Most common price: £495 (86 days, 100.0%)
Price range: £495 - £495
Price levels: 1 different prices over 86 days
Description
This study covers the latent demand outlook for diabetic retinopathy treatments across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for diabetic retinopathy treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic retinopathy treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Actavis, Aerpio, Alcon Laboratories, Alimera Sciences, Allergan, Ampio Pharmaceuticals, Bausch Health, Bayer, BCN Peptides, F. Hoffmann-La Roche, Genentech, Glycadia, IDx Technologies, IRIDEX, Kowa Company, Lumenis, Novartis, Oxurion, Parexel International Corporation, Pfizer, Regeneron Pharmaceuticals, Sirnaomics, ThromboGenics, and Valon Lasers. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B0BP9RSG9H
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 28 November 2022
- Listed Since
- 08 December 2022
Similar Products You Might Like
99% match
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in Japan
£495.00
30 Oct 2026
99% match
The 2023-2028 Outlook for Diabetic Retinopathy Treatments in China
£495.00
02 Nov 2026
99% match
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in China
£495.00
29 Oct 2026
99% match
Proliferative Diabetic Retinopathy Treatment Outlook 2023-2028
£490.00
26 Aug 2026
99% match
US Proliferative Diabetic Retinopathy Treatment Outlook 2023-2028
£520.00
26 Aug 2026
97% match
The 2023-2028 Outlook for Macular Degeneration Treatments in Japan
£495.00
28 Oct 2026
97% match
Diabetic Retinopathy: Methods and Protocols - Research Guide
Humana
£106.00
02 Oct 2026
97% match
Diabetic Retinopathy: A Glance At Molecular Level: Gene polymorphisms, Antioxidant status, Potential biomarkers and Risk factors
LAP Lambert Academic Publishing
£64.00
23 Sep 2026
97% match
Pathobiology of Diabetic Retinopathy: Diabetes, Diabetic Retinopathy and Medicinal Plants
LAP Lambert Academic Publishing
£66.00
22 Sep 2026
97% match
Early Events in Diabetic Retinopathy and Intervention Strategies
IntechOpen
£113.24
01 Oct 2026
97% match
Macular Degeneration Treatment Outlook in India 2023-2028
£515.00
26 Aug 2026
97% match
US Macular Degeneration Treatment Outlook 2023-2028 Study
£520.00
26 Aug 2026
97% match
World Outlook for Diabetic Macular Edema 2025-2030 Study
Price unavailable
97% match
Uveitis Drugs in India Market Outlook 2023-2028 Report
£515.00
28 Aug 2026
97% match
The 2026-2031 World Outlook for Diabetic Macular Edema
£885.00
02 Sep 2026
97% match
Dry Eye Syndrome Treatment Outlook in India 2023-2028
£515.00
08 Nov 2026
97% match
The 2023-2028 Outlook for Eye Drops in Japan
£495.00
03 Nov 2026
97% match
Diabetic Retinopathy - IntechOpen Medical Reference
IntechOpen
£130.98
01 Oct 2026
97% match
US Dry Eye Syndrome Treatment Outlook 2023-2028 Report
£520.00
07 Nov 2026
97% match
The 2023-2028 Outlook for Dry Eye Syndrome Treatments in China
£495.00
06 Nov 2026
97% match
Anti-VEGF Diabetic Macular Edema Outlook 2023-2028 Report
£490.00
28 Oct 2026
96% match
The 2023-2028 Outlook for Diabetes Treatments in Japan
£495.00
03 Nov 2026
96% match
Therapeutic Targets for Diabetic Retinopathy: A Translational Approach
Elsevier
£33.32
17 Sep 2026
96% match
The 2023-2028 Outlook for Myopia and Presbyopia Treatments in Japan
£495.00
05 Nov 2026